Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

Share Price is delayed by 15 minutes
Get Live Data
8.50    0.36 (4.24%)
Bid:
8.00
Ask:
9.00
Spread: 1.00 (12.50%)
Market Cap: £561.06m
AGY Live PriceLast checked at - London Stock Exchange

Intraday Allergy Thera. Share Chart

BLOCK LISTING SIX MONTHLY RETURN

16 Jul 2018 08:53

RNS Number : 7205U
Allergy Therapeutics PLC
16 July 2018
 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

(Note: Italicised terms have the same meaning as given in the Listing Rules.)

Date: 11 JULY 2018

 

Name of applicant:

ALLERGY THERAPEUTICS PLC

Name of scheme:

Allergy Therapeutics plc 2013 Long Term Incentive Plan

Period of return:

From:

21 Nov 2017

To:

11 July 2018

Balance of unallotted securities under scheme(s) from previous return:

10,000,000

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

-

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

 2,050,848

 

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

 7,949,152

 

 

Name of contact:

Sara Goldsbrough

Telephone number of contact:

+44 (0) 7966 165719 

 

 

Total Voting Rights

 

The total number of voting rights of the company is 596,168,616. This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the share capital of the company under the FCA's Disclosure and Transparency Rules.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRSFSSWMFASEIW
Date   Source Headline
26th Jun 20239:25 amRNSForm 8.5 (EPT/RI)
23rd Jun 202311:48 amRNSForm 8.5 (EPT/RI)
23rd Jun 202310:48 amBUSForm 8.3 - The Allergy Therapeutics Plc
22nd Jun 20239:55 amBUSForm 8.3 - THE ALLERGY THERAPEUTICS PLC
22nd Jun 20238:45 amRNSForm 8.5 (EPT/RI)
21st Jun 20239:38 amRNSForm 8.5 (EPT/RI)
20th Jun 202312:49 pmRNSForm 8.5 - Allergy Therapeutics plc
20th Jun 20239:57 amBUSForm 8.3 - The Allergy Therapeutics Plc
20th Jun 20239:05 amRNSForm 8.5 (EPT/RI)
19th Jun 20237:30 amRNSRestoration - Allergy Therapeutics PLC
19th Jun 20237:01 amRNSInterim Results and Lifting Suspension in Trading
19th Jun 20237:00 amRNSPublication of Annual Report and Accounts 2022
9th Jun 20237:00 amRNSAllergy Therapeutics shares key findings at EAACI
3rd May 20239:09 amRNSForm 8.3 - Allergy Therapeutics plc
27th Apr 20232:15 pmRNSResult of General Meeting
24th Apr 20237:00 amRNSSouthern Fox: Form 8.3 – Allergy Therapeutics Plc
21st Apr 20237:00 amRNSFORM 8 (OPD) – Allergy Therapeutics plc
20th Apr 20235:29 pmRNSProject Zebra Rule 2.9 Announcement
19th Apr 20237:00 amRNSSkin-prick testing completes in PROTECT Trial
17th Apr 20232:30 pmRNSForm 8 OPD SkyGem Acquisition Limited Replacement
17th Apr 202310:30 amRNSForm 8 (OPD) SkyGem Acquisition Limited
11th Apr 202310:10 amBUSForm 8.3 - The Allergy Therapeutics Plc
6th Apr 20232:01 pmRNSStatement Regarding Possible Mandatory Cash Offer
6th Apr 20232:01 pmRNS£40.75 million Facility with Equity Financing
6th Apr 20232:00 pmRNSTrading and Business Update
29th Mar 20237:00 amRNSPublication of Interim Results Delayed
27th Mar 20237:00 amRNSPatients dosed in VLP Peanut PROTECT trial
8th Mar 20235:28 pmRNSBlock Listing Interim Review
3rd Mar 20237:00 amRNSPDMR Dealing
7th Feb 20236:29 pmRNSResult of AGM
20th Jan 20237:00 amRNSHalf-Year Trading Update 2023
13th Jan 20235:27 pmRNSNOTICE OF 2022 ANNUAL GENERAL MEETING
3rd Jan 20237:30 amRNSSuspension - Allergy Therapeutics plc
29th Dec 202211:05 amRNSSecond Price Monitoring Extn
29th Dec 202211:00 amRNSPrice Monitoring Extension
29th Dec 20229:05 amRNSSecond Price Monitoring Extn
29th Dec 20229:00 amRNSPrice Monitoring Extension
29th Dec 20227:00 amRNSAnnual Report and Accounts Delayed
28th Dec 20227:00 amRNSDirector Resignation
8th Dec 20227:00 amRNSKey updates on Grass MATA MPL and VLP Peanut
6th Dec 20227:00 amRNSAppointment of Non-Executive Directors
21st Nov 20227:00 amRNSAppointment of Interim CFO
28th Oct 20227:00 amRNSAllergy to resume UK manufacturing production
19th Oct 20223:39 pmRNSHolding(s) in Company
17th Oct 20221:27 pmRNSAllergy Therapeutics – Result of GM
4th Oct 20227:00 amRNSUK manufacturing update
29th Sep 202212:00 pmRNSAllergy Therapeutics at Investor Meet Company
29th Sep 20227:00 amRNSSubscription and Debt Financing
29th Sep 20227:00 amRNSUnaudited Preliminary Results 2022
5th Sep 20227:00 amRNSAllergy Therapeutics at H.C. Wainwright Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.